Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis

Author(s): Mihwa Kim, Minwoo Baek, Dae Joon Kim*

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 29 , 2017

Become EABM
Become Reviewer
Call for Editor


Protein tyrosine phosphorylation is a crucial signaling mechanism that plays a role in epithelial carcinogenesis. Protein tyrosine kinases (PTKs) control various cellular processes including growth, differentiation, metabolism, and motility by activating major signaling pathways including STAT3, AKT, and MAPK. Genetic mutation of PTKs and/or prolonged activation of PTKs and their downstream pathways can lead to the development of epithelial cancer. Therefore, PTKs became an attractive target for cancer prevention. PTK inhibitors are continuously being developed, and they are currently used for the treatment of cancers that show a high expression of PTKs. Protein tyrosine phosphatases (PTPs), the homeostatic counterpart of PTKs, negatively regulate the rate and duration of phosphotyrosine signaling. PTPs initially were considered to be only housekeeping enzymes with low specificity. However, recent studies have demonstrated that PTPs can function as either tumor suppressors or tumor promoters, depending on their target substrates. Together, both PTK and PTP signal transduction pathways are potential therapeutic targets for cancer prevention and treatment.

Keywords: Carcinogenesis, tyrosine phosphorylation, PTK, PTP, EGFR, IGF-1R, STAT3, AKT.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [4226 - 4246]
Pages: 21
DOI: 10.2174/1381612823666170616082125
Price: $65

Article Metrics

PDF: 35
PRC: 1